
|Videos|January 9, 2017
The Possibility for Immunotherapy in Neoadjuvant Bladder Cancer Treatment
Author(s)Geoffrey Sklar, MD
Geoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses the possibility for immunotherapy as a neoadjuvant treatment in bladder cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
2
Teclistamab/Talquetamab Reduces Risk of Progression by 89% in R/R Multiple Myeloma
3
Advanced Renal Cell Carcinoma: Tailoring Second-Line Therapy After Prior Immunotherapy
4
IMNN-001 Plus Chemo Cuts MRD Rate in Frontline Ovarian Cancer
5































